Kaken Pharmaceutical Co., Ltd. completed the acquisition of ARTham Therapeutics Inc for ¥5.5 billion.
Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of ARTham Therapeutics Inc from a group of investors for ¥5.5 billion on December 13, 2021. Kaken has acquired 53.3% each of ARTham's common stock, class A stock or class B stock, or ARTham's stock acquisition rights. The common shares and class shares in ARTham that are to remain in the possession of the Sellers have been changed to non-voting common shares and class shares, therefore the ratio of voting rights in ARTham held by Kaken has become 100%. The sellers will be able to collect payments in Kaken's common stock equivalent up to ¥7.2 billion based on four strategic milestones.